Dr. Reddy’s Share Price in Focus; Revenue Grows 3.2% in FY26 Results

Dr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter and financial year ended March 31, 2026, under International Financial Reporting Standards (IFRS).

For FY26, the company reported consolidated revenues of ₹335,933 million, registering a 3.2% year-on-year increase compared to the previous financial year. EBITDA for the year stood at ₹76,595 million, accounting for 22.8% of total revenues.

Profit Before Tax (PBT) came in at ₹54,817 million, representing 16.3% of revenues, while Profit After Tax (PAT) attributable to equity holders reached ₹42,850 million, equivalent to 12.8% of annual revenues.

Q4FY26 Performance Under Pressure

During Q4FY26, Dr. Reddy’s reported revenues of ₹75,162 million, declining 11.6% year-on-year and 13.9% sequentially compared to Q3FY26.

Gross margin for the quarter stood at 44.8%, significantly lower than 55.6% reported in Q4FY25 and 53.6% in Q3FY26. EBITDA during the quarter was reported at ₹9,807 million, representing 13% of quarterly revenues.

Quarterly profitability also remained under pressure. Profit Before Tax for Q4FY26 stood at ₹1,991 million, contributing 2.6% to revenues, while Profit After Tax attributable to equity holders came in at ₹2,201 million, accounting for 2.9% of revenues.

Final Dividend Recommendation

The company has recommended a final dividend of ₹8 per equity share having a face value of ₹1 each for the financial year 2025-26, subject to shareholders’ approval at the upcoming Annual General Meeting (AGM). The record date for determining eligible shareholders entitled to receive the dividend has been fixed as July 10, 2026.

Dr. Reddy’s Share Price Today

On May 13, 2026, Dr. Reddy’s share price opened at ₹1,245.60, touching the day’s low at ₹1,230.00, as of 11:47 AM on the NSE.

Also Read: Dr. Reddy's Share Price in Focus as Health Canada Approves First Generic Semaglutide Injection!

Conclusion

Dr. Reddy’s Laboratories delivered steady annual revenue growth and strong FY26 profitability despite a challenging fourth quarter marked by declining margins and lower earnings. The company’s long-term performance continues to reflect its strong presence in the pharmaceutical sector and diversified global operations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.